Elafibranor (Iqirvo®): A Comprehensive Monograph on a First-in-Class PPAR Agonist for the Treatment of Primary Biliary Cholangitis

I. Executive Summary and Drug Profile

Introduction

Elafibranor, marketed under the proprietary name Iqirvo®, is a first-in-class, orally administered, once-daily dual peroxisome proliferator-activated receptor (PPAR) alpha (PPARα) and delta (PPARδ) agonist.[1] It has received accelerated or conditional approval in major global jurisdictions, including the United States and the European Union, for the treatment of Primary Biliary Cholangitis (PBC).[2] The approved indication is for adult patients who have demonstrated an inadequate response to, or who are intolerant of, the established first-line therapy, ursodeoxycholic acid (UDCA).[5] This monograph provides an exhaustive analysis of Elafibranor's pharmacology, the pivotal clinical evidence supporting its approval, its comprehensive safety profile, and its therapeutic position within the evolving landscape of PBC management.

Key Attributes

Elafibranor's novel mechanism of action, targeting the fundamental metabolic and inflammatory pathways of PBC, represents a significant departure from existing therapeutic modalities.[7] Its regulatory approvals are primarily based on the robust results of the pivotal Phase 3 ELATIVE trial, which demonstrated a statistically and clinically significant improvement in the primary biochemical endpoint—a composite of alkaline phosphatase (ALP) and total bilirubin levels—compared to placebo.[9] A defining characteristic that distinguishes Elafibranor from the alternative second-line therapy, obeticholic acid (OCA), is its favorable profile concerning pruritus. Pruritus is a common and often debilitating symptom of PBC that can be exacerbated by OCA, whereas Elafibranor has been shown to not worsen this symptom, thereby addressing a critical unmet need in patient management.[7]

Table 1: Elafibranor Drug Identification and Properties

Property	Details	Source(s)
Non-proprietary Name (INN)	Elafibranor	1
Proprietary Name	Iqirvo®	2
DrugBank ID	DB05187	2
CAS Number	923978-27-2	11
Type	Small Molecule	2
Synonyms/Code Names	GFT505	12
Chemical Formula	C22​H24​O4​S	11
Molecular Weight	384.49 g/mol	11
IUPAC Name	2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid	11

II. Development History and Global Regulatory Status

Discovery and Early Development by GENFIT

Elafibranor was discovered and developed internally by GENFIT, a French biopharmaceutical company with over two decades of experience in liver disease research.[15] The molecule, initially designated GFT505, was first explored for a range of metabolic conditions, reflecting its broad activity on lipid and glucose homeostasis. These early investigations included clinical development for hyperlipidemia, type 2 diabetes, and, most notably, non-alcoholic steatohepatitis (NASH).[14] The NASH program advanced to a Phase 3 trial before its development for that indication was discontinued in 2020 following a futility analysis, after which the company pivoted to focus on the promising application in PBC.[14]

Strategic Partnership with Ipsen

In a pivotal strategic move in December 2021, GENFIT entered into a long-term partnership with Ipsen, a global biopharmaceutical company. This agreement granted Ipsen exclusive worldwide rights (excluding Greater China, where rights were licensed to Terns Pharmaceuticals) to develop, manufacture, and commercialize Elafibranor for PBC.[14] The structure of this agreement is illustrative of a common and effective strategy in the modern biopharmaceutical industry, where a research-focused entity de-risks a novel asset through late-stage development before partnering with a larger firm possessing the global infrastructure for commercialization. The deal involved a substantial upfront payment of €120 million to GENFIT, with eligibility for up to €360 million in additional milestone payments and tiered double-digit royalties of up to 20%.[17] As part of the long-term commitment, Ipsen also acquired an 8% equity stake in GENFIT.[17] Under the terms, GENFIT retained responsibility for completing the 52-week double-blind period of the pivotal ELATIVE trial, after which Ipsen assumed control of all further clinical development and commercial activities.[17] The revenues from this partnership are intended to fund GENFIT's strategic shift toward developing a new pipeline focused on Acute-on-Chronic Liver Failure (ACLF).[16]

Regulatory Pathway and Approvals

Elafibranor's path to market was expedited by several key regulatory designations recognizing its potential to address an unmet medical need in a rare disease.

• United States (Food and Drug Administration - FDA): The FDA granted Elafibranor Breakthrough Therapy Designation for PBC in 2019.[20] Following the submission of positive data from the ELATIVE trial, Ipsen's New Drug Application (NDA) was accepted for Priority Review in December 2023.[1] On June 10, 2024, the FDA granted Accelerated Approval for Iqirvo® for the treatment of PBC in combination with UDCA in adults with an inadequate response, or as monotherapy in patients unable to tolerate UDCA.[1]
• European Union (European Medicines Agency - EMA): Elafibranor was designated an 'orphan medicine' for PBC by the EMA on July 25, 2019, a status reserved for treatments of rare diseases.[4] The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval in July 2024.[25] Subsequently, the European Commission granted Conditional Marketing Authorisation on September 19, 2024, for the same indication as the FDA.[4]

The accelerated and conditional nature of these approvals reflects a pragmatic regulatory approach tailored to rare and slowly progressing diseases like PBC. Regulators accepted a surrogate endpoint—the reduction in the biochemical marker ALP—as being "reasonably likely to predict clinical benefit".[9] This strategy prioritizes timely patient access to a promising therapy while acknowledging the logistical challenges of conducting pre-approval trials powered for hard clinical outcomes like death or liver transplantation, which can take many years to manifest. Consequently, both the FDA and EMA have mandated that continued approval is contingent upon the verification of clinical benefit in post-marketing confirmatory trials designed to assess these long-term outcomes.[4]

III. Comprehensive Pharmacological Profile

A. Mechanism of Action (Pharmacodynamics)

Elafibranor's therapeutic effects are derived from its unique activity as a dual agonist of two subtypes of the peroxisome proliferator-activated receptor family of nuclear receptors.

• Dual PPAR Agonism: Elafibranor is a first-in-class dual agonist of PPAR-α and PPAR-δ, with some in-vitro activity also demonstrated on PPAR-gamma (PPARγ).[1] PPARs are ligand-activated transcription factors that, upon binding, form a heterodimer with the retinoid X receptor (RXR) and bind to specific DNA sequences to regulate the expression of a broad portfolio of genes involved in critical metabolic and inflammatory processes.[8]
• PPAR-α Activation: PPAR-α is highly expressed in tissues with substantial fatty acid metabolism, such as the liver, heart, and muscle.[30] Activation of PPAR-α by Elafibranor enhances hepatic fatty acid β-oxidation, thereby reducing the accumulation of lipids in the liver. It also plays a key role in lipid homeostasis by regulating plasma levels of triglycerides and high-density lipoprotein (HDL) cholesterol.[2]
• PPAR-δ Activation: PPAR-δ is more ubiquitously expressed and its activation leads to a range of beneficial metabolic effects, including increased fatty acid transport and oxidation, improved insulin sensitivity, and enhanced glucose homeostasis.[2] Critically for an autoimmune condition like PBC, PPAR-δ activation also mediates potent anti-inflammatory actions through the inhibition of pro-inflammatory gene transcription.[8]
• Synergistic Effects in PBC: While the precise mechanism of action in PBC has not been fully elucidated, the therapeutic benefit is understood to arise from the combined, synergistic effects of dual PPAR-α and PPAR-δ activation.[2] This dual action allows Elafibranor to target multiple, distinct pathophysiological processes central to PBC:
• Inhibition of Bile Acid Synthesis: A key effect is the reduction of bile acid production. The activation of PPAR-α and PPAR-δ signaling pathways, potentially involving Fibroblast Growth Factor 21 (FGF21), leads to the downregulation of CYP7A1, the gene encoding the rate-limiting enzyme for the synthesis of bile acids from cholesterol.[1] This action decreases the overall bile acid pool, reducing the exposure of the liver to the toxic, hydrophobic bile acids that drive cholestatic injury and disease progression.[32]
• Anti-inflammatory and Anti-fibrotic Effects: The anti-inflammatory properties, largely attributed to PPAR-δ activation, are thought to mitigate the T-cell-mediated autoimmune assault on small bile ducts and the chronic inflammation that characterizes PBC.[8] By reducing inflammation, Elafibranor may also indirectly modulate the activation of hepatic stellate cells, which are the primary cell type responsible for the deposition of scar tissue, thereby exerting an anti-fibrotic effect.[8]

B. Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion - ADME)

The pharmacokinetic profile of Elafibranor and its major active metabolite underpins its convenient once-daily dosing regimen and its activity at the target organ.

• Absorption: Following oral administration of an 80 mg dose, Elafibranor is absorbed with a median time to reach peak plasma concentration (Tmax) of approximately 1.25 hours.[31]
• Distribution: Elafibranor is extensively bound to plasma proteins (approximately 99.7%), primarily serum albumin.[2] It exhibits a very large apparent volume of distribution (Vd/F) of 4731 L, which indicates that the drug does not remain confined to the bloodstream but distributes widely into the body's tissues.[2] This extensive tissue penetration is a desirable property for a drug targeting a specific organ like the liver.
• Metabolism: Elafibranor undergoes extensive metabolism, primarily forming a major active metabolite known as GFT1007. This conversion is mediated by the cytosolic enzyme 15-ketoprostaglandin 13-Δ reductase (PTGR1).[2] GFT1007 is a significant contributor to the drug's overall pharmacological effect, as its mean systemic exposure (AUC) at steady state is approximately 3.2-fold higher than that of the parent Elafibranor molecule.[2] GFT1007 is subsequently metabolized further by cytochrome P450 2C8 (CYP2C8) and UDP-glucuronosyltransferase (UGT) enzymes. The parent drug is also a substrate for CYP2J2 and various UGT isoforms.[31]
• Excretion: Elimination of Elafibranor and its metabolites occurs predominantly through the feces (77.1%), with a smaller fraction (19.3%) excreted in the urine.[31]
• Elimination Half-Life: Elafibranor is characterized by a long median elimination half-life of 70.2 hours.[2] In contrast, its active metabolite, GFT1007, has a considerably shorter half-life of 15.4 hours.[2] The combination of a long-acting parent drug that continuously generates a high-exposure active metabolite provides a strong pharmacokinetic rationale for the effective and convenient once-daily dosing schedule.

Table 2: Summary of Elafibranor Pharmacokinetic Parameters

Parameter	Value	Clinical Implication	Source(s)
Tmax (Median)	1.25 hours	Rapid absorption after oral dose.	31
Protein Binding	~99.7% (to serum albumin)	Low potential for removal by dialysis; potential for displacement interactions, although not highlighted as a major concern.	2
Volume of Distribution (Vd/F)	4731 L	Extensive distribution into tissues, including the target organ (liver).	2
Major Active Metabolite	GFT1007 (AUC is 3.2-fold higher than parent drug)	GFT1007 is a major contributor to the overall therapeutic effect.	2
Metabolism Enzymes	Elafibranor: PTGR1, CYP2J2, UGTs GFT1007: CYP2C8, UGTs	Multiple metabolic pathways; potential for drug interactions with inhibitors/inducers of these enzymes.	2
Elimination Half-Life (Median)	Elafibranor: 70.2 hours GFT1007: 15.4 hours	Long half-life of the parent drug supports sustained exposure and a convenient once-daily dosing regimen.	2
Route of Excretion	Feces: 77.1% Urine: 19.3%	Primarily eliminated via the hepatobiliary route.	31

IV. Clinical Efficacy in Primary Biliary Cholangitis: The ELATIVE Trial

The primary clinical evidence establishing the efficacy of Elafibranor in PBC is derived from the pivotal Phase 3 ELATIVE trial.

Study Design

ELATIVE (NCT04526665) was a multinational, randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the efficacy and safety of Elafibranor.[7] The trial enrolled 161 adult patients diagnosed with PBC who had either an inadequate biochemical response to UDCA (defined by an ALP level at least 1.67 times the ULN) or were intolerant to UDCA.[9] Patients were randomized in a 2:1 ratio to receive either Elafibranor 80 mg orally once daily or a matching placebo for a duration of 52 weeks.[10]

Patient Population

The demographic and baseline characteristics of the study population were consistent with those typically seen in PBC clinical practice. The mean age of participants was 57.1 years, 96% were female, and 91% were White.[9] The vast majority of patients (95%) were receiving concomitant UDCA therapy, positioning the trial primarily as an evaluation of Elafibranor as an add-on treatment.[9] The cohort had evidence of active disease at baseline, with a mean ALP level of 322 U/L.[9]

Primary Endpoint

The primary efficacy outcome of the ELATIVE trial was the rate of biochemical response at Week 52. This was a composite endpoint, with response defined as a patient meeting all three of the following criteria [7]:

1. An alkaline phosphatase (ALP) level less than 1.67 times the upper limit of normal (ULN), AND
2. A reduction in ALP of 15% or more from baseline, AND
3. A normal total bilirubin (TB) level.

Efficacy Results

The ELATIVE trial successfully met its primary and key secondary endpoints, demonstrating a significant therapeutic benefit for Elafibranor.

• Primary Endpoint: A substantially higher proportion of patients in the Elafibranor group achieved the primary composite endpoint. At 52 weeks, 51% of patients treated with Elafibranor met the criteria for biochemical response, compared to only 4% of patients in the placebo group. This difference was highly statistically significant (p<0.001), corresponding to a large placebo-adjusted response rate of 47 percentage points.[4]
• Key Secondary Endpoints:
• ALP Normalization: A more stringent measure of biochemical control, the normalization of ALP levels at Week 52, was achieved by 15% of patients in the Elafibranor arm, whereas 0% of patients in the placebo arm achieved this endpoint.[10]
• Pruritus (Itch): The effect on pruritus was a critical secondary outcome, given its impact on quality of life and its association with the alternative second-line therapy, OCA. The trial did not demonstrate a statistically significant difference between Elafibranor and placebo in the change from baseline on the Worst Itch Numeric Rating Scale (WI-NRS).[9] However, the data from other patient-reported outcome measures, such as the PBC-40 itch domain and the 5-D Itch score, numerically favored Elafibranor.[9] The most important clinical finding from this assessment was that Elafibranor treatment did not worsen pruritus, a key point of differentiation from OCA.[7]
• Lipid Profile: Consistent with its PPAR-agonist mechanism, treatment with Elafibranor resulted in numerically lower levels of total cholesterol, LDL-C, VLDL-C, and triglycerides when compared to placebo.[9]

The data on pruritus, while not meeting statistical significance for improvement on the primary scale, holds profound clinical implications. The central finding is not that Elafibranor is an effective anti-pruritic agent, but rather that it is a biochemically potent drug that does not carry the liability of exacerbating itch. This directly addresses the main drawback of its primary competitor, OCA, which is known to cause or worsen pruritus in a majority of patients, often leading to dose reduction or discontinuation.[7] This distinction establishes a clear clinical niche for Elafibranor in patients for whom pruritus is a significant concern.

Table 3: Key Efficacy Outcomes from the ELATIVE Phase 3 Trial

Endpoint	Elafibranor 80 mg (n=108)	Placebo (n=53)	Treatment Difference (95% CI) / p-value	Source(s)
Biochemical Response at Week 52 (Primary)	51%	4%	47% (32 to 57); p < 0.001	10
ALP Normalization at Week 52	15%	0%	15%	10
Change in WI-NRS Score from Baseline	No significant difference	-	Not statistically significant	9

V. Safety and Tolerability Profile

Overview

In clinical trials, Elafibranor has demonstrated a generally favorable tolerability profile, with the majority of adverse events reported as mild to moderate in severity.[8] However, several specific risks have been identified that require careful monitoring and patient management.

Common Adverse Events

The most frequently reported adverse events involve the musculoskeletal and gastrointestinal systems.

• More Common Adverse Events (>5% incidence):
• Musculoskeletal: Muscle pain (myalgia) (7%), pain or swelling in the arms or legs without injury, arthralgia (8%), and fracture (6%).[5]
• Gastrointestinal: Constipation (8%), diarrhea (11%), dry mouth (5%), heartburn/gastroesophageal reflux disease (6%), abdominal pain (11%), nausea (11%), and vomiting (11%).[5]
• General: Weight gain or loss (5-23%), rash (5%).[5]
• Less Common Adverse Events (1-5% incidence):
• Dizziness, gastroenteritis, increased blood creatinine, anemia, increased creatine phosphokinase (CPK), and cholelithiasis (gallstones) (3%).[5]

Serious Adverse Events and Warnings/Precautions

The product labeling for Iqirvo® includes several important warnings and precautions based on events observed in the clinical development program.

• Myalgia, Myopathy, and Rhabdomyolysis: Muscle-related symptoms are a known risk. Myalgia or myopathy, with or without elevations in CPK, have occurred in patients treated with Elafibranor, both as monotherapy and when used concomitantly with HMG-CoA reductase inhibitors (statins).[27] A case of rhabdomyolysis leading to acute kidney injury was reported in a patient with baseline cirrhosis who was also on a statin.[31] It is recommended to assess patients for myalgia and myopathy prior to initiating therapy and to consider periodic assessment (clinical examination, CPK measurement) during treatment. The medication should be interrupted if there is new onset or worsening of muscle symptoms.[9]
• Bone Fractures: An increased incidence of fractures was observed in the Elafibranor arm of the ELATIVE trial (6%).[5] Clinicians should consider fracture risk and monitor bone health as part of routine patient management.[9]
• Drug-Induced Liver Injury (DILI): Although intended to treat a liver disease, Elafibranor can, in some cases, cause or worsen liver injury. Clinicians should obtain baseline liver tests and continue to monitor them during therapy. The drug should be interrupted if liver tests worsen or if signs of clinical hepatitis (e.g., jaundice, dark urine, clay-colored stools, severe stomach pain) develop.[5] Elafibranor is not recommended for use in patients with decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).[9]
• Hypersensitivity Reactions: Serious, life-threatening allergic reactions have been reported, manifesting as rash, skin itching, swelling of the face or throat, fast heartbeat, or difficulty breathing or swallowing. Such reactions require immediate medical attention and permanent discontinuation of the drug.[5]
• Gallstones and Biliary Obstruction: Elafibranor may increase the risk of developing gallstones (cholelithiasis), which can potentially lead to biliary obstruction. Patients should be instructed to report any symptoms suggestive of obstruction, such as severe right upper quadrant pain with nausea and vomiting or jaundice.[5]

Table 4: Common and Serious Adverse Events Associated with Elafibranor

Frequency Category	Adverse Reaction	Clinical Management Note	Source(s)
More Common (>5%)	Myalgia, Arthralgia, Fracture, Diarrhea, Abdominal Pain, Nausea, Vomiting, Constipation, GERD, Weight Gain	Monitor for musculoskeletal symptoms and bone health. Gastrointestinal effects are often transient.	5
Less Common (1-5%)	Dizziness, Rash, Increased Blood Creatinine, Anemia, CPK Increased, Cholelithiasis	Monitor renal function and CPK periodically. Counsel patients on symptoms of gallstones.	31
Serious (Warnings)	Myopathy/Rhabdomyolysis, Drug-Induced Liver Injury (DILI), Hypersensitivity Reactions, Biliary Obstruction	Requires immediate interruption or permanent discontinuation of therapy. Requires baseline and ongoing monitoring of CPK and LFTs.	5

VI. Clinical Use and Patient Management

A. Dosing and Administration

• The recommended dosage of Iqirvo® is one 80 mg tablet taken orally once daily.[5]
• The tablet can be taken with or without food.[9]
• Patients should be counseled to take the medication exactly as prescribed and not to increase the dose or frequency, as doing so may increase the risk of side effects.[5]

B. Use in Specific Populations

• Hepatic Impairment: No dose adjustment is necessary for patients with mild hepatic impairment. However, for patients with moderate or severe hepatic impairment (Child-Pugh B or C) or those with decompensated cirrhosis, the use of Elafibranor is not recommended, and discontinuation of therapy should be considered.[9]
• Renal Impairment: No dosage modification is required for patients with mild, moderate, or severe renal impairment.[9]
• Geriatric Use (≥ 65 years): Clinical studies have not identified specific problems that would limit the usefulness of Elafibranor in the elderly population, and no dose adjustment is recommended. A slight increase in drug exposure was observed in healthy elderly subjects compared to younger subjects, but this was not deemed clinically significant.[5]
• Pregnancy and Lactation: Elafibranor is contraindicated in pregnancy as it may cause fetal harm. A negative pregnancy test must be verified before initiating treatment in females of reproductive potential.[5] There are insufficient data regarding the use of Elafibranor during breastfeeding to determine the risk to the infant.[5]

C. Pre-Treatment and Ongoing Monitoring

A systematic approach to patient evaluation and monitoring is essential for the safe and effective use of Elafibranor.

• Baseline Evaluation: Before starting therapy, the following assessments are required:

1. Musculoskeletal Assessment: Evaluate the patient for any pre-existing muscle pain or myopathy.[9]
2. Liver Function Tests: Obtain baseline liver tests, including ALT, AST, total bilirubin, and ALP.[9]
3. Pregnancy Status: Verify that females of reproductive potential are not pregnant via a pregnancy test.[9]

• Ongoing Monitoring: During treatment, clinicians should perform regular monitoring:

1. Liver Tests: Periodically monitor liver function tests to assess for therapeutic response and to detect any signs of drug-induced liver injury.[5]
2. Musculoskeletal Symptoms: Monitor for new or worsening muscle pain or weakness. Consider periodic measurement of CPK levels, especially in patients with symptoms or those on concomitant statins.[27]
3. Bone Health: Monitor for signs and symptoms of fractures and consider overall bone health in long-term management.[9]
4. Liver Decompensation: In patients with cirrhosis, monitor closely for signs of clinical decompensation (e.g., new or worsening ascites, jaundice, encephalopathy).[9]

VII. Clinically Significant Drug-Drug Interactions

Overview

Elafibranor's metabolic profile indicates it is a weak inducer of the CYP3A4 enzyme, and its absorption can be affected by other medications. These properties create the potential for clinically significant drug-drug interactions that require careful management.[31]

Key Interactions

• Bile Acid Sequestrants: Agents such as cholestyramine, colesevelam, and colestipol can bind to Elafibranor in the gastrointestinal tract, thereby reducing its absorption and systemic exposure, which may compromise its efficacy. To mitigate this interaction, Elafibranor must be administered at least 4 hours before or 4 hours after the administration of a bile acid sequestrant, or at the greatest possible interval.[5]
• Hormonal Contraceptives: Elafibranor is a weak inducer of CYP3A4, an enzyme responsible for the metabolism of many hormonal contraceptives (e.g., ethinyl estradiol and progestins). Co-administration can reduce the systemic exposure of these hormones, potentially leading to contraceptive failure and/or an increase in breakthrough bleeding. Therefore, females of reproductive potential using hormonal contraceptives should be advised to switch to an effective non-hormonal method of contraception or to add a reliable barrier method during treatment with Elafibranor and for at least 3 weeks after the final dose.[27]
• HMG-CoA Reductase Inhibitors (Statins): There is an additive risk of myopathy, myalgia, and rhabdomyolysis when Elafibranor is co-administered with statins. Patients on this combination require close monitoring for signs and symptoms of muscle injury. Interruption of Elafibranor treatment should be considered if new or worsening muscle-related symptoms occur.[27]
• Rifampin: Rifampin is a potent inducer of various drug-metabolizing enzymes. Its co-administration may increase the metabolism of Elafibranor and its active metabolite, GFT1007, leading to reduced systemic exposure and a potentially delayed or suboptimal biochemical response. If a patient on Elafibranor must initiate rifampin, their biochemical response (ALP and bilirubin) should be monitored closely.[27]

Table 5: Clinically Significant Drug-Drug Interactions and Management

Interacting Drug Class/Agent	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Source(s)
Bile Acid Sequestrants	Adsorption in the GI tract, reducing Elafibranor absorption.	Reduced systemic exposure and efficacy of Elafibranor.	Administer Elafibranor at least 4 hours before or 4 hours after the sequestrant.	5
Hormonal Contraceptives	Weak induction of CYP3A4 by Elafibranor.	Reduced exposure to progestin/estradiol, leading to risk of contraceptive failure.	Advise use of an effective non-hormonal contraceptive method or addition of a barrier method during and for 3 weeks after treatment.	27
Statins	Additive pharmacodynamic effect on muscle tissue.	Increased risk of myalgia, myopathy, and rhabdomyolysis.	Monitor closely for muscle injury. Interrupt Elafibranor if symptoms develop or worsen.	27
Rifampin	Induction of metabolizing enzymes.	Reduced systemic exposure of Elafibranor and its active metabolite.	Monitor biochemical response (ALP, bilirubin) if rifampin is initiated.	27

VIII. Comparative Therapeutic Analysis and Clinical Context

The PBC Treatment Landscape

The management of PBC follows a stepwise algorithm, with Elafibranor positioned as a second-line agent.

• First-Line Therapy: Ursodeoxycholic acid (UDCA) has been the cornerstone of PBC treatment for decades.[7] UDCA is a hydrophilic bile acid that is thought to work through multiple mechanisms, including displacing more toxic hydrophobic bile acids, stimulating bile flow, protecting cholangiocytes from injury, and exerting immunomodulatory effects.[38] While effective in many, up to 40% of patients exhibit an inadequate biochemical response to UDCA, leaving them at an elevated risk for disease progression to cirrhosis and liver failure.[10]
• Second-Line Therapy: For patients who are UDCA non-responders or are intolerant, second-line therapy is indicated. Prior to the approval of Elafibranor, the only approved agent in this setting was Obeticholic Acid (OCA).[7] The introduction of Elafibranor provides a crucial alternative, fundamentally altering the clinical decision-making process for these patients.

Elafibranor vs. Obeticholic Acid (OCA)

A direct comparison between Elafibranor and OCA is essential for understanding their respective roles in clinical practice. Although no head-to-head clinical trials have been conducted, a comparative analysis can be made based on their distinct pharmacological profiles and data from their respective pivotal Phase 3 trials (ELATIVE for Elafibranor, POISE for OCA).

• Mechanism of Action: The two drugs operate through entirely different signaling pathways. Elafibranor is a dual PPAR-α/δ agonist, modulating gene expression related to lipid metabolism, inflammation, and bile acid synthesis.[7] In contrast, OCA is a potent agonist of the Farnesoid X Receptor (FXR), a nuclear receptor that functions as the body's primary sensor for bile acids. FXR activation potently suppresses bile acid synthesis by downregulating CYP7A1.[43]
• Efficacy on Biochemical Markers: Both agents have demonstrated substantial efficacy in improving the surrogate biochemical markers used for regulatory approval. In the Phase 3 POISE trial, 46-47% of patients treated with OCA (5-10 mg or 10 mg doses) met the primary composite biochemical endpoint at 12 months.[35] This is comparable to the 51% response rate observed with Elafibranor in the ELATIVE trial.[10] An indirect comparison performed as part of a health technology assessment suggested that Elafibranor may lead to a higher rate of liver function test normalization, though these findings were associated with uncertainty.[7]
• The Critical Differentiator - Pruritus: The most significant distinction between the two drugs lies in their effect on pruritus. In the POISE trial, pruritus was the most common adverse event with OCA, reported by 56-68% of patients on active treatment compared to 38% on placebo, and was often severe enough to lead to treatment discontinuation.[35] In stark contrast, Elafibranor did not worsen pruritus in the ELATIVE trial.[7]

The availability of Elafibranor transforms the second-line treatment decision for PBC. It moves the conversation beyond a singular focus on biochemical efficacy, where the agents are broadly comparable, to a more patient-centered approach. The patient's symptom burden, specifically the presence and severity of pruritus, now becomes a primary factor in selecting the most appropriate therapy. For a patient with significant baseline pruritus, or one who is highly averse to the risk of developing it, Elafibranor emerges as the logical first choice for second-line treatment.

Table 6: Comparative Profile of Second-Line Therapies for PBC: Elafibranor vs. Obeticholic Acid

Feature	Elafibranor (Iqirvo®)	Obeticholic Acid (Ocaliva®)
Mechanism of Action	Dual Peroxisome Proliferator-Activated Receptor (PPAR) α/δ Agonist	Farnesoid X Receptor (FXR) Agonist
Pivotal Phase 3 Trial	ELATIVE	POISE
Primary Endpoint Response Rate	~51%	~46-47%
Effect on Pruritus (Itch)	Does not worsen pruritus; numerically favorable on some patient-reported outcome scales.	Commonly causes or worsens pruritus (56-68% incidence); can be severe and dose-limiting.
Key Adverse Events of Concern	Myalgia/Myopathy, Bone Fractures, Drug-Induced Liver Injury	Pruritus, Hepatic Decompensation and Failure (in patients with cirrhosis)
Standard Dosing	80 mg once daily	5 mg once daily, titrated to 10 mg once daily based on tolerability and response.
Source(s)	7	7

IX. Future Directions and Unanswered Questions

Confirmatory Trials and Long-Term Outcomes

The central outstanding question for Elafibranor is whether the demonstrated improvements in surrogate biochemical markers will translate into long-term clinical benefits. The accelerated and conditional approvals from the FDA and EMA are predicated on this assumption, but it must be proven. Both agencies have mandated the completion of long-term confirmatory trials designed to assess the drug's impact on hard clinical outcomes, such as time to liver decompensation (e.g., development of ascites, variceal bleeding, or hepatic encephalopathy), need for liver transplantation, and overall survival.[4] The ongoing ELFIDENCE study is intended to provide these crucial data.[34]

Exploration of Other Indications

Given its potent metabolic, anti-inflammatory, and potential anti-fibrotic effects, Elafibranor is being investigated for other chronic liver diseases. The most promising of these is Primary Sclerosing Cholangitis (PSC), a rare and severe cholestatic liver disease that currently has no approved medical therapies.[3] Data from the Phase 2 ELMWOOD trial in patients with PSC have been encouraging, demonstrating a favorable safety profile and significant, dose-dependent improvements in liver biochemical parameters, including ALP, over 12 weeks of treatment. These results suggest that PSC may represent a viable future indication for Elafibranor.[21]

Long-Term Safety Profile

While the 52-week data from the ELATIVE trial are reassuring, the full long-term safety profile of Elafibranor remains to be characterized. Ongoing extension studies will be critical for understanding the chronic risks associated with the drug, particularly concerning the observed signals for bone fractures and myopathy.

Potential for Third-Line Use

The possibility of using Elafibranor as a third-line agent for patients who have failed or are intolerant to both UDCA and OCA has been suggested by clinical experts.[7] While its distinct mechanism of action makes this a plausible concept, there is currently no clinical evidence to support its efficacy or safety in this specific patient population.

X. Conclusion and Expert Recommendations

Synthesis of Risk-Benefit Profile

Elafibranor (Iqirvo®) represents a significant and welcome advancement in the therapeutic armamentarium for Primary Biliary Cholangitis. It offers a novel pharmacological approach through its dual PPAR-α/δ agonist mechanism, which translates into robust improvements in validated surrogate markers of disease progression. The overall safety profile observed in its pivotal trial is generally manageable, although it carries specific risks, including myopathy and bone fractures, that necessitate diligent clinical monitoring.

Therapeutic Role and Recommendations

Elafibranor is appropriately positioned as a second-line therapy for adult patients with PBC who have an inadequate response to or are intolerant of first-line UDCA. Its most compelling clinical advantage is its favorable profile with respect to pruritus, a debilitating symptom that limits the use of the alternative second-line agent, obeticholic acid.

Based on the available evidence, the following recommendations are made for its use in clinical practice:

• Patient Selection: Elafibranor should be considered the preferred second-line agent for UDCA non-responders who have significant baseline pruritus, are intolerant to OCA due to pruritus, or wish to avoid the risk of OCA-induced pruritus.
• Monitoring: Clinicians must adhere strictly to the recommended pre-treatment and ongoing monitoring guidelines, with particular attention to assessing musculoskeletal symptoms (with periodic CPK measurement as clinically indicated), liver function tests, and bone health.
• Patient Counseling: Critical counseling points for patients include the importance of adherence, the need to report any new or worsening muscle pain or symptoms of liver injury immediately, and the absolute requirement for females of reproductive potential to use effective non-hormonal contraception.
• Clinical Context: It is important for both clinicians and patients to understand the conditional nature of Elafibranor's approval. While it provides a valuable new treatment option based on strong biochemical data, its definitive impact on long-term clinical outcomes, such as survival and the prevention of liver decompensation, awaits confirmation from ongoing long-term studies.

Works cited

1. Iqirvo (elafibranor) FDA Approval History - Drugs.com, accessed September 19, 2025, https://www.drugs.com/history/iqirvo.html
2. Elafibranor: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 19, 2025, https://go.drugbank.com/drugs/DB05187
3. Elafibranor: First Approval - PubMed, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/39110316/
4. Iqirvo, INN-elafibranor - European Medicines Agency, accessed September 19, 2025, https://www.ema.europa.eu/en/documents/overview/iqirvo-epar-medicine-overview_en.pdf
5. Elafibranor (oral route) - Side effects & dosage - Mayo Clinic, accessed September 19, 2025, https://www.mayoclinic.org/drugs-supplements/elafibranor-oral-route/description/drg-20571306
6. Elafibranor for previously treated primary biliary cholangitis | Guidance - NICE, accessed September 19, 2025, https://www.nice.org.uk/guidance/ta1016/chapter/2-Information-about-elafibranor
7. Elafibranor for previously treated primary biliary cholangitis - NCBI Bookshelf, accessed September 19, 2025, https://www.ncbi.nlm.nih.gov/books/NBK611619/
8. What is the therapeutic class of Elafibranor? - Patsnap Synapse, accessed September 19, 2025, https://synapse.patsnap.com/article/what-is-the-therapeutic-class-of-elafibranor
9. Elafibranor (IQIRVO) National Drug Monograph November ... - VA.gov, accessed September 19, 2025, https://www.va.gov/formularyadvisor/DOC_PDF/MON_Elafibranor_IQIRVO_Primary_Biliary_Cholangitis_Nov_2024.pdf
10. Latest FDA approved drug Elafibranor (Iqirvo): a novel prospect for treatment of primary biliary cholangitis - PMC, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11918794/
11. 2-(2,6-Dimethyl-4-((1E)-3-(4-(methylthio)phenyl)-3-oxo-1-propen-1-yl)phenoxy)-2-methylpropanoic acid - PubChem, accessed September 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Elafibranor
12. Elafibranor | CAS#923978-27-2 | PPA agonist | MedKoo, accessed September 19, 2025, https://www.medkoo.com/products/15637
13. Elafibranor (GFT505, CAS Number: 923978-27-2) | Cayman Chemical, accessed September 19, 2025, https://www.caymanchem.com/product/23508/elafibranor
14. Elafibranor - Alzheimer's Drug Discovery Foundation, accessed September 19, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Elafibranor.pdf
15. GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval, accessed September 19, 2025, https://genfit.gcs-web.com/news-releases/news-release-details/genfit-ipsens-iqirvor-elafibranor-receives-eu-approval-first
16. GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis, accessed September 19, 2025, https://ir.genfit.com/news-releases/news-release-details/genfit-historic-milestone-achieved-us-fda-accelerated-approval/
17. GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership, accessed September 19, 2025, https://ir.genfit.com/news-releases/news-release-details/genfit-ipsen-and-genfit-enter-exclusive-licensing-agreement/
18. Elafibranor (GFT505) | PPARα/δ Agonist - MedchemExpress.com, accessed September 19, 2025, https://www.medchemexpress.com/Elafibranor.html
19. Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine, accessed September 19, 2025, https://www.ipsen.com/us/press-releases/results-from-ipsens-elative-pivotal-phase-iii-trial-of-elafibranor-in-pbc-presented-as-late-breaking-data-at-aasld-congress-and-published-in-new-england-journal-of-medicine/
20. GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC), accessed September 19, 2025, https://ir.genfit.com/news-releases/news-release-details/genfit-updates-2024-outlook-following-acceptance-elafibranor/
21. Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication - Ipsen, accessed September 19, 2025, https://www.ipsen.com/press-releases/late-breaking-elafibranor-primary-sclerosing-cholangitis-psc-data-demonstrates-favorable-safety-profile-and-significant-efficacy-in-second-potential-rare-liver-disease-indication-3067100/
22. Ipsen, Genfit's Elafibranor Wins FDA Approval for Primary Biliary Cholangitis - BioSpace, accessed September 19, 2025, https://www.biospace.com/ipsen-genfit-s-elafibranor-wins-fda-approval-for-primary-biliary-cholangitis
23. Search Orphan Drug Designations and Approvals - FDA, accessed September 19, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=693919
24. Iqirvo | European Medicines Agency (EMA), accessed September 19, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/iqirvo
25. Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis - Investor Relations | GENFIT, accessed September 19, 2025, https://ir.genfit.com/news-releases/news-release-details/genfit-positive-opinion-ema-committee-ipsens-iqirvor-elafibranor/
26. EU Approves Ipsen's Iqirvo® (elafibranor) as First New Primary Biliary Cholangitis Therapy in a Decade - Patsnap Synapse, accessed September 19, 2025, https://synapse.patsnap.com/blog/eu-approves-ipsens-iqirvo-elafibranor-as-first-new-primary-biliary-cholangitis-therapy
27. Multi-PPAR activation treatment approach | Official HCP Site - IQIRVO® (elafibranor), accessed September 19, 2025, https://www.iqirvohcp.com/choosing-iqirvo/mechanism-of-action
28. Drug Trials Snapshots: IQIRVO - FDA, accessed September 19, 2025, https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-iqirvo
29. Elafibranor Efficacy and Safety in People with Primary Biliary Cholangitis, accessed September 19, 2025, https://www.biomedicine.video/gastroenterology-hepatology/elafibranor-efficacy-and-safety-in-people-with-primary-biliary-cholangitis
30. What is the mechanism of Elafibranor? - Patsnap Synapse, accessed September 19, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-elafibranor
31. Iqirvo (elafibranor) dosing, indications, interactions, adverse effects ..., accessed September 19, 2025, https://reference.medscape.com/drug/iqirvo-elafibranor-4000432
32. Elafibranor: MedlinePlus Drug Information, accessed September 19, 2025, https://medlineplus.gov/druginfo/meds/a624039.html
33. medlineplus.gov, accessed September 19, 2025, https://medlineplus.gov/druginfo/meds/a624039.html#:~:text=Elafibranor%20is%20in%20a%20class,that%20accumulate%20in%20the%20liver.
34. The effects of elafibranor in people with primary biliary cholangitis: a plain language summary - Taylor & Francis Online, accessed September 19, 2025, https://www.tandfonline.com/doi/abs/10.1080/23995270.2024.2444861
35. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis - PubMed, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/27532829/
36. IQIRVO® (elafibranor) | Official Patient Site, accessed September 19, 2025, https://www.iqirvo.com/
37. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis | Clinical Research Trial Listing - CenterWatch, accessed September 19, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT02823353/fenofibrate-in-combination-with-ursodeoxycholic-acid-in-primary-biliary-cirrhosis
38. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/15062194/
39. pmc.ncbi.nlm.nih.gov, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7045744/#:~:text=One%20of%20the%20main%20mechanisms,the%20hepatocyte%20(Stiehl%201999).
40. What is the mechanism of action of Ursodeoxycholic acid (UDCA)? - Dr.Oracle AI, accessed September 19, 2025, https://www.droracle.ai/articles/131581/udca-mechanism-of-action-
41. Ursodeoxycholic Acid - StatPearls - NCBI Bookshelf, accessed September 19, 2025, https://www.ncbi.nlm.nih.gov/books/NBK545303/
42. The efficacy of ursodeoxycholic acid and Bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study | Request PDF - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/publication/229462243_The_efficacy_of_ursodeoxycholic_acid_and_Bezafibrate_combination_therapy_for_primary_biliary_cirrhosis_A_prospective_multicenter_study
43. Obeticholic Acid - StatPearls - Nova Southeastern University, accessed September 19, 2025, https://nova.elsevierpure.com/files/42814215/Obeticholic%20Acid
44. What is the mechanism of Obeticholic acid? - Patsnap Synapse, accessed September 19, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-obeticholic-acid
45. Obeticholic Acid—A Pharmacological and Clinical Review - MDPI, accessed September 19, 2025, https://www.mdpi.com/2673-9879/3/1/17
46. Obeticholic Acid - StatPearls - NCBI Bookshelf, accessed September 19, 2025, https://www.ncbi.nlm.nih.gov/books/NBK567735/
47. How OCALIVA® Works: MOA for PBC, accessed September 19, 2025, https://ocalivahcp.com/moa/
48. Obeticholic acid: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 19, 2025, https://go.drugbank.com/drugs/DB05990
49. P100 Evaluation of response to obeticholic acid in primary biliary cholangitis treatment – single centre retrospective observational study | Gut, accessed September 19, 2025, https://gut.bmj.com/content/73/Suppl_3/A74.2
50. Intercept Presents New Sub-Analyses of Phase 3 POISE Data Showcasing the Effect of OCA on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024, accessed September 19, 2025, https://www.interceptpharma.com/about-us/news/?id=2893223